Table 2.
Correlations between GPR30 and EGFR expression and clinicopathological factors
|
Variables |
Expression of GPR30 |
p value |
Expression of EGFR |
p value |
||
|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | |||
| Age |
54.0 ± 12.7 |
54.3 ± 12.2 |
0.49 |
54.3 ±11.9 |
53.9 ±13.5 |
0.84 |
| Premenopausal |
40 (60.6%) |
26 (39.4%) |
0.80 |
27 (40.9%) |
39 (59.1%) |
0.39 |
| Postmenopausal |
60 (60.6%) |
36 (39.4%) |
|
33 (33.3%) |
63 (66.7%) |
|
| BMI |
21.5 ± 2.7 |
22.6 ± 4.2 |
0.04 |
21.4±3.6 |
22.2±2.8 |
0.11 |
| Borderline malignancy |
1 (10.0%) |
9 (90.0%) |
0.0016 |
0 (0%) |
10 (100%) |
0.012 |
| FIGO stage I |
26 (66.7%) |
13 (33.3%) |
0.31 |
13 (33.3%) |
26 (66.7%) |
0.77 |
| II |
11 ( 78.6%) |
3 (21.4%) |
|
7 (50.0 %) |
7 (50.0%) |
|
| III |
47 (61.3%) |
30 (38.7%) |
|
32 (41.6%) |
45 (58.4%) |
|
| IV |
15 (68.2%) |
7 (31.8%) |
|
8 (36.4%) |
14 (63.6%) |
|
| Histology |
|
|
|
|
|
|
| Borderline malignancy |
1 (10.0%) |
9 (90.0%) |
0.0016 |
0 (0%) |
10 (100%) |
0.012 |
| Serous adenocarcinoma |
46 (75.4%) |
15 (24.6%) |
<;0.001 |
24 (39.3%) |
37 (60.7%) |
0.42 |
| Endometrioid adenocarcinoma |
25 (83.3%) |
5 (16.7%) |
|
11 (36.7%) |
19 (63.3%) |
|
| Mucinous adenocarcinoma |
14 (73.7%) |
5 (26.3%) |
|
8 (42.1%) |
11 (57.9%) |
|
| Clear cell adenocarcinoma |
6 (20.7%) |
23 (79.3%) |
|
14 (48.3%) |
15 (51.7%) |
|
| Others |
8 (61.5%) |
5 (38.5%) |
|
3 (23.1%) |
10 (76.9%) |
|
| Recurrence |
|
|
0.30 |
|
|
0.31 |
| ≤ 6M |
13 (68.4%) |
6 (31.6%) |
|
9 (47.4%) |
10 (52.6%) |
|
| > 6M |
43 (67.2%) |
21 (32.8%) |
|
20 (31.3%) |
44 (68.7%) |
|
| No recurrence |
44 (55.7%) |
35 (44.3%) |
|
31 (39.2%) |
48 (60.8%) |
|
| 5-year survival |
|
|
0.56 |
|
|
0.86 |
| Alive |
63 (61.8%) |
39 (38.2%) |
|
35 (34.3%) |
67 (65.7%) |
|
| Dead | 37 (61.7%) | 23 (38.3%) | 25 (41.7%) | 35 (58.3%) | ||